Axsome Therapeutics (FRA:19X) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:19X Axsome Therapeutics Inc FRA:19X
30 GF Score
Price €210.60
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:19X
30GF Score
Axsome Therapeutics Inc FRA:19X
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
30GF Score

Get the complete analysis for FRA:19X

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€210.60
Price